ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABVC ABVC BioPharma, Inc.

Market Closed 09-11 16:00:00 EDT

0.9801

+0.0039

+0.40%

盘后1.02

+0.0399+4.07%

19:59 EDT

High1.01	Low0.9762	Vol97.68K
Open1.01	D1 Closing0.9762	Amplitude3.46%
Mkt Cap26.12M	Tradable Cap21.39M	Total Shares26.65M
T/O95.99K	T/O Rate0.45%	Tradable Shares21.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABVC","market":"US","secType":"STK","nameCN":"ABVC BioPharma, Inc.","latestPrice":0.9801,"timestamp":1789156800000,"preClose":0.9762,"halted":0,"volume":97681,"hourTrading":{"tag":"盘后","latestPrice":1.02,"preClose":0.9801,"latestTime":"19:59 EDT","volume":899,"amount":909.891,"timestamp":1789171140005,"change":0.0399,"changeRate":0.04071,"amplitude":0.04071},"delay":0,"changeRate":0.003995082974800261,"floatShares":21826200,"shares":26654365,"eps":-0.285468,"marketStatus":"Market Closed","change":0.0039,"latestTime":"09-11 16:00:00 EDT","open":1.01,"high":1.01,"low":0.9762,"amount":95988.48619705,"amplitude":0.034624,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.285468,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1627963200000,"exchange":"NASDAQ","adjPreClose":0.9762,"preHourTrading":{"tag":"盘前","latestPrice":1.03,"preClose":0.9762,"latestTime":"09:25 EDT","volume":23,"amount":23.6400003,"timestamp":1789133100329,"change":0.0538,"changeRate":0.055112,"amplitude":0.040975},"postHourTrading":{"tag":"盘后","latestPrice":1.02,"preClose":0.9801,"latestTime":"19:59 EDT","volume":899,"amount":909.891,"timestamp":1789171140005,"change":0.0399,"changeRate":0.04071,"amplitude":0.04071},"volumeRatio":0.7442070581144994,"impliedVol":0.4964,"impliedVolPercentile":0.1673},"requestUrl":"/m/hq/s/ABVC","defaultTab":"news","newsList":[{"id":"2666910405","title":"Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2666910405","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666910405?lang=en_us&edition=fundamental","pubTime":"2026-09-10 22:25","pubTimestamp":1789050337,"startTime":"0","endTime":"0","summary":"Optimi Health (OPTH) announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with maj...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimi-health-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-for-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimi-health-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-for-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","BK4139","PSIL","GDOC","MEDX","NVIB","BK4007","OPTH","ABVC","HYLG","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372197","title":"Analyst Reiterates Buy on Definium Therapeutics, Maintains $75 Price Target Following De-Risking of DT120 ODT in MDD and GAD","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372197","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372197?lang=en_us&edition=fundamental","pubTime":"2026-09-09 03:25","pubTimestamp":1788895521,"startTime":"0","endTime":"0","summary":"Analyst Francois Brisebois of LifeSci Capital reiterated a Buy rating on Definium Therapeutics, retaining the price target of $75.00. Francois Bris...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-definium-therapeutics-maintains-75-price-target-following-de-risking-of-dt120-odt-in-mdd-and-gad-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-definium-therapeutics-maintains-75-price-target-following-de-risking-of-dt120-odt-in-mdd-and-gad-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","ABVC","ODT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665735956","title":"Mizuho survey shows no consensus into Alkermes ADHD data","url":"https://stock-news.laohu8.com/highlight/detail?id=2665735956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665735956?lang=en_us&edition=fundamental","pubTime":"2026-09-05 03:35","pubTimestamp":1788550508,"startTime":"0","endTime":"0","summary":"Mizuho conducted a survey of 13 investors ahead of Alkermes (ALKS)’ Phase 1b trial of ALKS-7290 in adult attention-deficit/hyperactivity disorder, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mizuho-survey-shows-no-consensus-into-alkermes-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mizuho-survey-shows-no-consensus-into-alkermes-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","ALKS","IBRN","PSCH","MEDX","BK4139","FBT","ADHD","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664637869","title":"Supernus Pharmaceuticals (SUPN) On Chloe Kim ADHD Push And Whether Undervalued Looks Priced In","url":"https://stock-news.laohu8.com/highlight/detail?id=2664637869","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664637869?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:23","pubTimestamp":1788294236,"startTime":"0","endTime":"0","summary":"Olympic snowboarder Chloe Kim’s new awareness partnership with Supernus Pharmaceuticals (SUPN) puts extra focus on Qelbree and adult ADHD and may lead some investors to recheck how the stock’s current pricing reflects its ADHD portfolio.\nSupernus Pharmaceuticals’ stock is trading at US$44.21, with the 1-day share price return of 1.10% partially offsetting a weaker year to date share price return that is down 10.63%. The 5-year total shareholder return of 61% points to a much stronger longer...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/supernus-pharmaceuticals-supn-on-chloe-kim-adhd-push-and-whe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/supernus-pharmaceuticals-supn-on-chloe-kim-adhd-push-and-whe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ABVC","SUPN","BK4139","ADHD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664886702","title":"Blinklab Showcases AI Smartphone Platform for Autism and ADHD Diagnosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2664886702","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664886702?lang=en_us&edition=fundamental","pubTime":"2026-09-01 07:15","pubTimestamp":1788218106,"startTime":"0","endTime":"0","summary":"Blinklab Limited ( ($AU:BB1) ) has issued an update. Blinklab Limited has outlined its AI-driven smartphone platform designed for neurometric testi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/blinklab-showcases-ai-smartphone-platform-for-autism-and-adhd-diagnosis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/blinklab-showcases-ai-smartphone-platform-for-autism-and-adhd-diagnosis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAPW","QTOC","AIPO","BK4139","VTHR","AAPY","AAPU","ARTY","AAPE","AAPB","APLY","AAPX","CHAT","ABVC","ADHD","AGIX","AAPD","IOSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663300925","title":"Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2663300925","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663300925?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:30","pubTimestamp":1788179400,"startTime":"0","endTime":"0","summary":"Chloe Kim is partnering with Supernus to highlight the importance of recognizing ADHD in adults and help empower individuals to work with their doctors to develop a tailored treatment plan.While ADHD ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353291/19871/en/chloe-kim-teams-up-with-qelbree-the-1-prescribed-branded-non-stimulant-adhd-treatment-to-help-empower-people-navigating-adhd.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","CNS","PD","EMPW.U","BK4023","BK4139","CDC","LU1169590202.USD","ADHD","ABVC","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662841350","title":"Lilly’s Brenipatide Steps Into Phase 3: A New Long-Term Play in Depression Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2662841350","media":"TIPRANKS","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662841350?lang=en_us&edition=fundamental","pubTime":"2026-08-28 00:30","pubTimestamp":1787848252,"startTime":"0","endTime":"0","summary":"Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 3 RENEW-MDD-2 study from Eli Lilly And Company tests br...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lillys-brenipatide-steps-into-phase-3-a-new-long-term-play-in-depression-care?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lillys-brenipatide-steps-into-phase-3-a-new-long-term-play-in-depression-care?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700161","title":"ABVC BioPharma Completes BioKey Cayman Spin-Off Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700161","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662700161?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:59","pubTimestamp":1787835580,"startTime":"0","endTime":"0","summary":"ABVC BioPharma ( ($ABVC) ) has issued an announcement. On August 21, 2026, ABVC BioPharma completed the legal and structural separation of its subs...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abvc-biopharma-completes-biokey-cayman-spin-off-transaction?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abvc-biopharma-completes-biokey-cayman-spin-off-transaction?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662707967","title":"ABVC Biopharma Completes BioKey Cayman Spinoff, Distributes 15% Stake to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2662707967","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662707967?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:32","pubTimestamp":1787833972,"startTime":"0","endTime":"0","summary":"ABVC Biopharma completes BioKey Cayman spinoff, distributes 15% stake to shareholdersABVC BioPharma completed a partial separation of BioKey Cayman via a pro rata dividend of about 15% of its ordinary","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL98x8RB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659815471","title":"Press Release: Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2659815471","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659815471?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:30","pubTimestamp":1786624200,"startTime":"0","endTime":"0","summary":"contract development and manufacturing organization, to complete the. requested CMC work and advance process validation for CTx-1301, which. -- Product Distribution: On July 21, 2026, the Company signed an exclusive. services agreement with Prasco, LLC to establish the commercial. distribution infrastructure for the launch of CTx-1301, providing. designed to support broad national availability across maj","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443895.HKD","TM","BK4555","LU0170899867.USD","ADHD","LU2746668974.SGD","IE00BFXG1179.USD","LU0267386448.USD","LU2237443465.HKD","BK4604","IE00BZ1G4Q59.USD","PRGS","IE00BKVL7J92.USD","LU0149725797.USD","LU0971096721.USD","ABVC","CMC","LU2237443622.USD","IE00BHPRN162.USD","CING","BK4585","BK4097","BK4006","LU2065732104.USD","LU1363072403.SGD","LU2237443978.SGD","BK4139","LU0882574139.USD","BK4007","LU2237443549.SGD","LU2746668461.USD","BK4099","IE00B1BXHZ80.USD","03160","LU2237443382.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659900693","title":"ABVC Biopharma FY26 Q2 Net Loss Narrows 65% to $810,481","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900693","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900693?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:14","pubTimestamp":1786565671,"startTime":"0","endTime":"0","summary":"ABVC Biopharma FY26 Q2 net loss narrows 65% to $810,481ABVC Biopharma posted a Q2 net loss of $810,481, narrowing 65% from the year-earlier quarter.Operating loss tightened to $779,526 as operating ex","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL7mLjFj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659909150","title":"ABVC BioPharma Delays BioKey (Cayman) Share Distribution to Aug. 21 from Aug. 3 in 8-K Amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2659909150","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659909150?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:06","pubTimestamp":1786550771,"startTime":"0","endTime":"0","summary":"ABVC BioPharma delays BioKey (Cayman) share distribution to Aug. 21 from Aug. 3 in 8-K amendmentABVC Biopharma amended its 8-K to delay the planned BioKey (Cayman) share distribution to Aug. 21, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLbq9CXb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659920909","title":"ABVC Biopharma - Biokey (Cayman) Share Distribution Rescheduled for August 21, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2659920909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659920909?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:04","pubTimestamp":1786550673,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN449156:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659909927","title":"ABVC Biopharma - Postpones Biokey (Cayman) Share Distribution - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2659909927","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659909927?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:04","pubTimestamp":1786550673,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN449156:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658150918","title":"Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2658150918","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658150918?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:30","pubTimestamp":1786451400,"startTime":"0","endTime":"0","summary":"Findings further validate Cingulate’s Precision Timed Release (PTR) platform and its trimodal drug delivery approachKANSAS CITY, Kan., Aug.  11, 2026  (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3342703/0/en/cingulate-publishes-peer-reviewed-data-demonstrating-ctx-1301-s-differentiated-pharmacokinetic-profile.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","CING","BK4139","BK4007","ADHD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657165660","title":"Collegium Q2 2026 earnings: ADHD growth offsets pain portfolio pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=2657165660","media":"TradingKey","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657165660?lang=en_us&edition=fundamental","pubTime":"2026-08-07 09:54","pubTimestamp":1786067655,"startTime":"0","endTime":"0","summary":"Collegium Pharmaceutical’s Q2 2026 net product revenue rose 6% to $199.9 million, while GAAP diluted EPS swung to a $0.46 loss from earnings of $0.34. Adjusted EBITDA increased 8% to $113.8 million as JORNAY PM revenue climbed 41% and AZSTARYS contributed $12.9 million for a partial quarter, offsetting a 9% decline in the pain portfolio. The company lowered full-year product revenue and adjusted EBITDA guidance because authorized-generic Nucynta pricing was weaker than expected, while raising its AZSTARYS revenue range.","market":"fut","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock10.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock10.jpg"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262086846-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOTE","DECU","PMDE","ADHD","RGLO","GXDW","VGFPF","ABVC","FEBU","JOYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657507137","title":"Yukiguni Maitake Sees FY Net Y2.54b","url":"https://stock-news.laohu8.com/highlight/detail?id=2657507137","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657507137?lang=en_us&edition=fundamental","pubTime":"2026-08-06 14:30","pubTimestamp":1785997800,"startTime":"0","endTime":"0","summary":"Yukiguni Maitake Co. Ltd. also released the following forecasts:. Results are based on IFRS accounting standards.This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657951555","title":"BlinkLab's ADHD European Case-Control Study Achieves High Sensitivity, Specificity Results; Shares Jump 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657951555","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657951555?lang=en_us&edition=fundamental","pubTime":"2026-08-05 08:39","pubTimestamp":1785890370,"startTime":"0","endTime":"0","summary":"BlinkLab (ASX:BB1) said its European case-control study of smartphone-based digital neurobehavioral biomarkers in children between the ages of 6 years and 17 years, both with and without attention-def","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EPV","BB1.AU","BK4139","ADHD","BK7094","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656302870","title":"NASDAQ Trade Halt Halt News Pending at 04:43 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2656302870","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656302870?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:43","pubTimestamp":1785789839,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTHALT NEWS PENDING AT 04:43 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nAQN2MCX7Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656037500","title":"Press Release: Helus Pharma Appoints Michael Halstead as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2656037500","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656037500?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:40","pubTimestamp":1785757200,"startTime":"0","endTime":"0","summary":"Former President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the company, which was subsequently acquired by Johnson & JohnsonExperienced executive with a proven track r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","R","BK4232","BK4555","BK4585","BK4604","TM","03160","ABVC","BK4588","BK4022","BK4099"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abvcpharma.com","stockEarnings":[{"period":"1week","weight":0.0208},{"period":"1month","weight":0.0208},{"period":"3month","weight":-0.1764},{"period":"6month","weight":-0.2283},{"period":"1year","weight":-0.6462},{"period":"ytd","weight":-0.5399}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.072395},{"month":2,"riseRate":0.125,"avgChangeRate":-0.057705},{"month":3,"riseRate":0.625,"avgChangeRate":0.040736},{"month":4,"riseRate":0.375,"avgChangeRate":0.01167},{"month":5,"riseRate":0.5,"avgChangeRate":0.035623},{"month":6,"riseRate":0.375,"avgChangeRate":1.167092},{"month":7,"riseRate":0.375,"avgChangeRate":-0.130229},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.065211},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.0425},{"month":10,"riseRate":0.375,"avgChangeRate":-0.067045},{"month":11,"riseRate":0.625,"avgChangeRate":0.051458},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012195}],"exchange":"NASDAQ","name":"ABVC BioPharma, Inc.","nameEN":"ABVC BioPharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ABVC BioPharma, Inc.,ABVC,ABVC BioPharma, Inc.股票,ABVC BioPharma, Inc.股票老虎,ABVC BioPharma, Inc.股票老虎国际,ABVC BioPharma, Inc.行情,ABVC BioPharma, Inc.股票行情,ABVC BioPharma, Inc.股价,ABVC BioPharma, Inc.股市,ABVC BioPharma, Inc.股票价格,ABVC BioPharma, Inc.股票交易,ABVC BioPharma, Inc.股票购买,ABVC BioPharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}